DDrare: Database of Drug Development for Rare Diseases

Orbcel-c (DrugBank: Orbcel-C)

2 diseases

ID	Disease name (Link within this page)	Number of trials
94	Primary sclerosing cholangitis	1
95	Autoimmune hepatitis	1

94. Primary sclerosing cholangitis [ 134 clinical trials, 105 drugs, (DrugBank: 37 drugs), 18 drug target genes, 131 drug target pathways]

Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 134 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02997878 (ClinicalTrials.gov)	December 7, 2018	13/12/2016	A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH	An Adaptive,Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis	Cholangitis, Sclerosing;Hepatitis, Autoimmune	Biological: Orbcel-C	University of Birmingham	European Union;NHS Blood and Transplant	Recruiting	18 Years	70 Years	All	56	Phase 1;Phase 2	United Kingdom

95. Autoimmune hepatitis [ 44 clinical trials, 57 drugs, (DrugBank: 26 drugs), 18 drug target genes, 108 drug target pathways]

Searched query = "Autoimmune hepatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 44 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02997878 (ClinicalTrials.gov)	December 7, 2018	13/12/2016	A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH	An Adaptive,Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis	Cholangitis, Sclerosing;Hepatitis, Autoimmune	Biological: Orbcel-C	University of Birmingham	European Union;NHS Blood and Transplant	Recruiting	18 Years	70 Years	All	56	Phase 1;Phase 2	United Kingdom